Last reviewed · How we verify
NCT06882239: SPINEPASS
SPINEPASS: SPINE Self-management Techniques for Persistent Headache After Concussion: Physical Therapy Targeting Autonomic and Dura Mater Function.
NA trial testing SPINEPASS Physical Therapy in Persistent Post-concussive Symptoms in 120 participants. Not yet recruiting.
30 March 2028
Quick facts
| Lead sponsor | The University of Queensland |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 May 2025 |
| Primary completion | 30 March 2028 |
| Estimated completion | 30 September 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SPINEPASS Physical Therapy
- Standard Physical Therapy
Conditions studied
- Persistent Post-concussive Symptoms — all drugs for Persistent Post-concussive Symptoms →
- Post Traumatic Headache — all drugs for Post Traumatic Headache →
Sponsor
The University of Queensland
Who can join
Adults 18 to 65, any sex, with Persistent Post-concussive Symptoms or Post Traumatic Headache. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective randomized controlled trial comparing two different physical therapy approaches to the treatment of posttraumatic headache with autonomic symptoms. AIM 1: To establish the efficacy of SPINEPASS against Standard Physical Therapy to reduce headache disability and impact amongst patients with persistent post-concussion headache. AIM 2: Demonstrate the superiority of SPINEPASS in the efficient self-management of headache. Demonstrate its appropriateness, acceptability, and feasibility and gain patient insights among patients with PPTH compared to standard PT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Physical Therapy Targeting Autonomic and Dura Mater Function: SPINEPASS Randomized Clinical Trial Protocol.
Treleaven J, Hammerle M, Swan A, Marsh L, et al · · 2026 · PMID 41324433 · DOI 10.1093/ptj/pzaf143
Verify or expand the search:
- PubMed search for NCT06882239
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The University of Queensland trials
Trials by the same sponsor.
- NCT06120673 — REmission in Membranous Nephropathy International Trial (REMIT) · Phase 3 · withdrawn
- NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
- NCT07114354 — Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Diseas · NA · not yet recruiting
- NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
- NCT06510699 — Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06882239 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Queensland
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06882239.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing